Kiwi Wealth Investments Limited Partnership purchased a new position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,354 shares of the biopharmaceutical company’s stock, valued at approximately $879,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Robeco Institutional Asset Management B.V. grew its holdings in shares of Regeneron Pharmaceuticals by 21.9% during the third quarter. Robeco Institutional Asset Management B.V. now owns 5,564 shares of the biopharmaceutical company’s stock valued at $2,247,000 after buying an additional 1,000 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 3.7% during the third quarter. Victory Capital Management Inc. now owns 8,785 shares of the biopharmaceutical company’s stock valued at $3,549,000 after buying an additional 315 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Regeneron Pharmaceuticals by 23.7% during the third quarter. Janney Montgomery Scott LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $2,269,000 after buying an additional 1,075 shares during the last quarter. Dupont Capital Management Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $390,000. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 22.9% during the third quarter. Commonwealth Equity Services LLC now owns 7,938 shares of the biopharmaceutical company’s stock valued at $3,207,000 after buying an additional 1,481 shares during the last quarter. 66.87% of the stock is currently owned by institutional investors and hedge funds.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $5,786,740. The disclosure for this sale can be found here. In the last quarter, insiders sold 134,754 shares of company stock valued at $55,439,356. Insiders own 12.42% of the company’s stock.
NASDAQ:REGN opened at $407.50 on Friday. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. The firm has a market capitalization of $44.53 billion, a price-to-earnings ratio of 20.58, a price-to-earnings-growth ratio of 1.68 and a beta of 1.20.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, beating the consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same period in the prior year, the company earned $5.23 earnings per share. The firm’s revenue was up 21.9% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current year.
REGN has been the topic of a number of research analyst reports. TheStreet raised shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, January 17th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price objective on the stock in a report on Friday, January 4th. BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Leerink Swann set a $483.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 7th. They noted that the move was a valuation call. Finally, Oppenheimer set a $440.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 2nd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $413.76.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Current Ratio
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.